Argiris A, Li S, Savvides P, et al. - Researchers focused on the impacts of bevacizumab (a humanized monoclonal antibody that targets vascular endothelial growth factor) added to platinum-based chemotherapy for treating recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Participants were 403 chemotherapy-naïve patients (or with prior platinum as a component of multimodal treatment completed ≥ 4 months earlier) with recurrent or metastatic SCCHN. The participants were randomly administered a platinum-based chemotherapy doublet with or without bevacizumab 15 mg/kg delivered intravenously every 3 weeks until progression of the disease. Chemotherapy could be stopped following six cycles if a maximum response was obtained. Findings revealed no improvement in overall survival with bevacizumab added to chemotherapy, but it led to improvements in the response rate and progression-free survival with increased toxicities.